Return to Colloquia & Seminar listing
Improving Computational Drug Design with a Top-Down Approach to Ligand Binding
Special Events| Speaker: | David Mobley, UC San Francisco |
| Location: | 2112 MSB |
| Start time: | Thu, Jan 19 2006, 4:10PM |
Description
A large part of the increasing success of modern medicine over the past 50
years is due to the development of modern drugs. Drug development is
amazingly expensive, however, and these costs as passed on to the consumer.
One major bottleneck in the drug design process is that there is currently
no reliable way to predict, given a target protein structure, which
potential drug-like molecules (ligands) will bind with high affinity to a
disease-associated active site. Thus the early stages of drug design
typically amount to simple trial and error for a large library of molecules
to identify potential drug molecules. Drug companies also employ so-called
computational Docking methods to assist with this stage. In Docking, a large
library of potential binders is screened computationally to try and identify
those which are most likely to bind well for experimental testing. All of
the major drug companies use these methods, but, while fast, they are
unfortunately quite unreliable. Measured binding affinities actually have a
stronger correlation with molecular weight than with the predictions of most
major Docking packages. Docking makes so many approximations that it is
difficult to know how to improve its results.
I will discuss my work to accurately calculate binding affinities with the
highest reasonable level of theory for a simple test system, with a
particular focus on cases where Docking predictions fail. My results show
that current molecular mechanics force fields are capable of doing far
better than Docking and not only accurately ranking potential binders but
also accurately calculating relative free energies of binding and accurately
identifying ligand bound orientations. Furthermore, I am working to learn
from these detailed methods how to improve Docking. For example, Docking
typically neglects most protein flexibility, and I am looking at how much
this approximation would affect the results, to assess how many of Docking's
failures are attributable to this approximation. Additionally, these results
include contributions to binding affinity due to both protein and ligand
entropies, which Docking currently neglects, and more sophisticated solvent
models; I am working to systematically add back in some of the
approximations Docking makes to assess the importance of these. I will also
discuss plans for future work, including application of the method to
systems of greater relevance to diseases, and ongoing experimental tests to
verify some predictions I have made for some particular ligands.
